表紙:癌遺伝子パネル検査およびプロファイルの世界市場 (2021-2025年):癌タイプ・用途・組織・遺伝子タイプ別の成長機会・カスタマイズ予測&分析・エグゼクティブ&コンサルタントガイド
市場調査レポート
商品コード
1016543

癌遺伝子パネル検査およびプロファイルの世界市場 (2021-2025年):癌タイプ・用途・組織・遺伝子タイプ別の成長機会・カスタマイズ予測&分析・エグゼクティブ&コンサルタントガイド

Genomic Cancer Panel and Profiling Markets by Cancer, by Application, by Tissue and by Gene Type with Screening Potential Market size, Customized Forecasting/Analysis, and Executive and Consultant Guides 2021-2025

出版日: | 発行: Howe Sound Research | ページ情報: 英文 564 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=111.25円
癌遺伝子パネル検査およびプロファイルの世界市場 (2021-2025年):癌タイプ・用途・組織・遺伝子タイプ別の成長機会・カスタマイズ予測&分析・エグゼクティブ&コンサルタントガイド
出版日: 2021年06月25日
発行: Howe Sound Research
ページ情報: 英文 564 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

癌遺伝子パネル検査およびプロファイルは、癌の診断および治療の様式を急速に変えつつあります。何百もの遺伝子に関する情報を癌の治療に用いることで、市場は爆発的に拡大しています。

当レポートでは、世界の癌遺伝子パネル検査およびプロファイルの市場を調査し、市場の定義と概要、市場構造・参入事業者、新型コロナウイルス感染症 (COVID-19) およびその他の市場影響因子の分析、産業における近年の展開、市場規模の推移・予測、癌タイプ・用途・組織・地域など各種区分別の内訳、主要企業のプロファイルなどをまとめています。

第1章 市場ガイド

第2章 イントロダクション・市場の定義

第3章 市場概要

  • 参入事業者
  • オンコゲノミクス
  • 癌の管理と診断
  • 導入フェーズ
  • 産業構造
  • 現在利用可能な大規模包括的アッセイ
  • 価格プロファイリング・全エクソーム(またはゲノム)シーケンス

第4章 市場動向

  • 成長推進因子
  • 成長抑制因子
  • 計装と自動化
  • 診断技術の開発

第5章 癌パネル・プロファイル:近年の進展

  • Dante Labs:Cambridge Cancer Genomicsを買収
  • Celemics・Strand:NGS解析のための統合プラットフォームで提携
  • Myriad Genetics:祖先の乳癌パネルを再キャリブレーション
  • Burning Rock:収益が増加
  • Caris Life Sciences:リキッドバイオプシー検査を拡大
  • OncoDiag:膀胱癌再発のマルチプレックス検査を発表
  • Intermountain・Myriad:検査提供を統合
  • Illumina・Geneseeq:中国で癌検査キットを提供
  • Exact Sciences:エンドツーエンドの癌検査を提供、など

第6章 主要企業のプロファイル

  • 10x Genomics, Inc
  • Abbott Diagnostics
  • AccuraGen Inc.
  • Adaptive Biotechnologies
  • Aethlon Medical
  • Agena Bioscience, Inc.
  • Agilent/Dako
  • Anchor Dx
  • ANGLE plc
  • ApoCell, Inc.
  • ArcherDx, Inc.
  • ARUP Laboratories
  • Asuragen
  • AVIVA Biosciences
  • Baylor Miraca Genetics Laboratories
  • Beckman Coulter Diagnostics
  • Becton, Dickinson and Company
  • BGI Genomics Co. Ltd
  • Bioarray Genetics
  • Biocartis
  • Biocept, Inc
  • Biodesix Inc.
  • BioFluidica
  • BioGenex
  • BioIVT
  • Biolidics Ltd
  • bioM?rieux Diagnostics
  • Bioneer Corporation
  • Bio-Rad Laboratories, Inc
  • Bio-Reference Laboratories
  • Bio-Techne
  • Bioview
  • Bolidics
  • Boreal Genomics
  • Bristol-Myers Squibb
  • Burning Rock
  • Cancer Genetics
  • Caris Molecular Diagnostics
  • Castle Biosciences, Inc.
  • Celemics
  • CellMax Life
  • Cepheid(Danaher)
  • Charles River Laboratories
  • Chronix Biomedical
  • Circulogene
  • Clinical Genomics
  • Cynvenio
  • Cytolumina Technologies Corp.
  • CytoTrack
  • Datar Cancer Genetics Limited
  • Diagnologix LLC
  • Diasorin S.p.A.
  • Enzo Life Sciences, Inc.
  • Epic Sciences
  • Epigenomics AG
  • Eurofins Scientific
  • Exact Sciences
  • Exosome Diagnostics
  • Exosome Sciences
  • Fabric Genomics
  • Fluidigm Corp
  • Fluxion Biosciences
  • Foundation Medicine
  • Freenome
  • FUJIFILM Wako Diagnostics
  • GeneFirst Ltd.
  • Genetron Holdings
  • GenomOncology
  • GILUPI Nanomedizin
  • Grail, Inc
  • Guardant Health
  • HalioDx
  • HansaBiomed
  • HeiScreen
  • Helomics
  • Horizon Discovery
  • HTG Molecular Diagnostics
  • iCellate
  • Illumina
  • Incell Dx
  • Inivata
  • Integrated Diagnostics
  • Invitae Corporation
  • Invivogen
  • Invivoscribe
  • Janssen Diagnostics
  • MDNA Life SCIENCES, Inc
  • MDx Health
  • Menarini Silicon Biosystems
  • Millipore Sigma
  • Miltenyi Biotec
  • MIODx
  • miR Scientific
  • Molecular MD
  • MyCartis
  • Myriad Genetics/Myriad RBM
  • NantHealth, Inc.
  • Natera
  • NeoGenomics
  • New Oncology
  • NGeneBio
  • Novogene Bioinformatics Technology Co., Ltd.
  • Oncocyte
  • OncoDNA
  • Ortho Clinical Diagnostics
  • Oxford Nanopore Technologies
  • Panagene
  • Perkin Elmer
  • Personal Genome Diagnostics
  • Personalis
  • Precipio
  • PrecisionMed
  • Promega
  • Qiagen Gmbh
  • Rarecells SAS
  • RareCyte
  • Roche Molecular Diagnostics
  • Screencell
  • Sense Biodetection
  • Serametrix
  • Siemens Healthineers
  • Silicon Biosystems
  • simfo GmbH
  • Singlera Genomics Inc
  • Singulomics
  • SkylineDx
  • Stratos Genomics
  • Sysmex Inostics
  • Tempus Labs, Inc.
  • Thermo Fisher Scientific Inc
  • Thrive Earlier Detection
  • Todos Medical
  • Trovagene
  • Variantyx
  • Volition
  • Vortex Biosciences

第7章 世界の癌遺伝子パネル検査・プロファイル市場

  • 市場概要:国別
  • 世界市場の概要:癌タイプ別
  • 世界市場の概要:用途別
  • 世界市場の概要:組織別
  • 世界市場の概要:生殖細胞系列・体細胞

第8章 市場分析・予測:癌タイプ別

  • 総市場
  • 乳癌
  • 結腸直腸癌
  • 婦人科
  • 血液癌
  • 前立腺癌
  • 肺癌
  • その他

第9章 市場分析・予測:用途別

  • 臨床試験
  • 製薬
  • 研究

第10章 市場分析・予測:組織タイプ別

  • 固形組織
  • 液体組織

第11章 市場分析・予測:生殖細胞系列・体細胞

  • 体細胞
  • 生殖細胞系列

第12章 潜在的市場機会

第13章 付録

図表

Table of Tables

  • Table 1: Market Shares
  • Table 2: Medicare Clinical Lab Expenditures Actual & Forecast 2014 to 2024 ($Billion)
  • Table 3: Market Players by Type
  • Table 4: The Base Pairs
  • Table 5: Current Assays
  • Table 6: Relevant Pricing Table
  • Table 7: Five Factors Driving Growth
  • Table 8: Four Factors Limiting Growth
  • Table 9: Key Diagnostic Laboratory Technology Trends
  • Table 10: Next Generation Sequencing Technologies - Speed and Cost
  • Table 11: - Global Cancer Panel Market by Region
  • Table 12: Global Market by Cancer Type
  • Table 13: Global Market by Application
  • Table 14: Global Market by Tissue
  • Table 15: Global Market Germline & Somatic
  • Table 16: Comprehensive Testing by Country
  • Table 17: Breast Cancer Gene Testing by Country
  • Table 18: Colorectal Cancer Gene Testing by Country
  • Table 19: Gynecological Cancer Testing by Country
  • Table 20: Blood Cancer Gene Testing by Country
  • Table 21: Prostate Cancer Gene Testing by Country
  • Table 22: Lung Cancer Gene Testing by Country
  • Table 23: Other Cancer Gene Testing by Country
  • Table 24: Clinical Testing by Country
  • Table 25: Pharmaceutical Testing by Country
  • Table 26: Research Testing by Country
  • Table 27: Solid Tissue Testing by Country
  • Table 28: Liquid Tissue Testing by Country
  • Table 29: Somatic by Country
  • Table 30: Germline by Country
  • Table 31: Potential Screening Market: Lung, Breast & Colorectal
  • Table 32: Potential Screening Market: Prostate, Other & All
  • Table 33: Potential Cancer Diagnosis Market Size
  • Table 34: Potential Cancer Management Market Size
  • Table 35: Foundation - Guardant 2016-17 Quarterly Revenue & Volume
  • Table 36: Foundation - Guardant 2018 Quarterly Revenue & Volume
  • Table 37: Foundation - Guardant 2019 Quarterly Revenue & Volume
  • Table 38: Foundation - Guardant 2020 Quarterly Revenue & Volume
  • Table 39: Foundation - Guardant 2021 Quarterly Revenue & Volume
  • Table 40: 2021 Laboratory Fee Schedule
  • Table 41: FDA Approved Human Genetic tests
  • Table 42: Pharmacogenomic Biomarkers
  • Table 43: FDA Approved Pharmacogenomic Tests

Table of Figures

  • Figure 1: Large Comprehensive Profiles - Company Market Shares Chart
  • Figure 2: VistSeq Hereditary Cancer Panel
  • Figure 3: Medicare Clinical Lab Expenditures 2014 to 2024 ($Million)
  • Figure 4: The Genomic Progression of Cancer
  • Figure 5: DNA Strands and Chromosomes
  • Figure 6: Karyogram of Human Chromosomes
  • Figure 7: Size of Various Genomes
  • Figure 8: Germline vs Somatic Mutations
  • Figure 9: Comparing Genomic Diagnostic and Traditional Testing
  • Figure 10: Percentage of World Population Over 65
  • Figure 11: Base Year Country Global Share
  • Figure 12: Global Market by Cancer - Base vs. Final Year
  • Figure 13: Cancer Panel Market Base Year
  • Figure 14: Cancer Panel Market Final Year
  • Figure 15: Cancer Type Share by Year
  • Figure 16: Cancer Type Segment Growth
  • Figure 17: Global Market by Cancer - Base vs. Final Year
  • Figure 18: Cancer Panel Market Base Year
  • Figure 19: Cancer Panel Market Final Year
  • Figure 20: Application Share by Year
  • Figure 21: Application Segment Growth
  • Figure 22: Global Market by Cancer - Base vs. Final Year
  • Figure 23: Cancer Panel Market Base Year
  • Figure 24: Cancer Panel Market Final Year
  • Figure 25: Tissue Share by Year
  • Figure 26: Tissue Segment Growth
  • Figure 27: Germline & Somatic - Base vs. Final Year
  • Figure 28: Germline & Somatic Market Base Year
  • Figure 29: Germline & Somatic Market Final Year
  • Figure 30: Germline & Somatic Share by Year
  • Figure 31: Germline & Somatic Segment Growth
  • Figure 32: Comprehensive Testing Growth
  • Figure 33: Breast Cancer Testing Growth
  • Figure 34: Colorectal Cancer Gene Testing Growth
  • Figure 35: Gynecological Cancer Testing Growth
  • Figure 36: Blood Cancer Gene Testing Growth
  • Figure 37: Prostate Cancer Gene Testing Growth
  • Figure 38: Lung Cancer Gene Testing Growth
  • Figure 39: Other Cancer Gene Testing Growth
  • Figure 40: Clinical Testing Growth
  • Figure 41: Pharmaceutical Testing Growth
  • Figure 42: Research Testing Growth
  • Figure 43: Solid Tissue Testing Growth
  • Figure 44: Liquid Tissue Testing Growth
  • Figure 45: Somatic Testing Growth
  • Figure 46: Germline Testing Growth
目次

OVERVIEW:

Cancer Gene Panels and Genomic Profiling are quickly changing the diagnosis and treatment of cancers. The market is moving out of a specialized niche and going mainstream as Oncologists begin routinely using information on the hundreds of genes related to cancer. The market is exploding as physicians use all the information they can get in the battle against cancer. While Pharmaceutical Companies see the potential to make nearly any therapy viable. The report has data on how test volumes have grown for the biggest players. Find out how this new way of understanding cancer will change cancer diagnostics forever.

Comprehensive panels, genomic profiling, high risk breast cancer panels. Learn all about how players are jockeying for position in a market that is being created from scratch. And some players are pulling way out in front and expanding globally. It is a dynamic market situation with enormous opportunity where the right diagnostic with the right support can command premium pricing. And the science is developing at the same time creating new opportunities with regularity. And the cost of sequencing continues to fall.

The report includes detailed breakouts for 18 Countries and 4 Regions. A detailed breakout for any country in the world is available to purchasers of the report.

ABOUT THE LEAD AUTHOR:

Mr. Greg Powell, B.SC., M.B.A is the President of Howe Sound Research. He is an experienced business and clinical professional. He is co-author of the paper "The Radioimmunoassay of Angiotensinogen by Antibody Trapping." He has worked in laboratory testing and management for over 20 years. Mr. Powell's education includes:

  • B.Sc. (Chemistry) University of BC
  • M.B.A. (Finance and Policy) University of BC
  • Market Research Seminar - Burke Institute
  • Finance for Senior Executives - Harvard Business School

Table of Contents

1. Market Guides

  • 1.1. Cancer Panel Market-Strategic Situation Analysis & COVID Update
  • 1.2. Large Comprehensive Cancer Panel Market-Situation Analysis
  • 1.3. Guide for Executives, Marketing, Sales and Business Development Staff
  • 1.4. Guide for Management Consultants and Investment Advisors
  • 1.5. Market Size and Shares-Large Comprehensive

2. Introduction and Market Definition

  • 2.1. What are Cancer Gene Panels and Profiling?
  • 2.2. The Sequencing Revolution
  • 2.3. Market Definition
    • 2.3.1. Revenue Market Size
  • 2.4. Methodology
    • 2.4.1. Authors
    • 2.4.2. Sources
  • 2.5. A Spending Perspective on Clinical Laboratory Testing
    • 2.5.1. An Historical Look at Clinical Testing

3. Market Overview

  • 3.1. Players in a Dynamic Market
    • 3.1.1. Academic Research Lab
    • 3.1.2. Diagnostic Test Developer
    • 3.1.3. Instrumentation Supplier
    • 3.1.4. Distributor and Reagent Supplier
    • 3.1.5. Independent Testing Lab
    • 3.1.6. Public National/regional lab
    • 3.1.7. Hospital lab
    • 3.1.8. Physician Office Labs
    • 3.1.9. Audit Body
    • 3.1.10. Certification Body
  • 3.2. Oncogenomics
    • 3.2.1. Carcinogenesis
    • 3.2.2. Chromosomes, Genes and Epigenetics
      • 3.2.2.1. Chromosomes
      • 3.2.2.2. Genes
      • 3.2.2.3. Epigenetics
    • 3.2.3. Cancer Genes
    • 3.2.4. Germline vs Somatic
    • 3.2.5. Gene Panels, Single Gene Assays and Multiplexing
    • 3.2.6. Genomic Profiling
    • 3.2.7. The Comprehensive Assay
    • 3.2.8. Changing Clinical Role
    • 3.2.9. The Cancer Screening Market Opportunity
  • 3.3. Cancer Management vs. Diagnosis
    • 3.3.1. The Role of Risk Assessment
    • 3.3.2. Diagnosis
    • 3.3.3. Managing
    • 3.3.4. Monitoring
  • 3.4. Phases of Adoption-Looking into The Future
  • 3.5. Structure of Industry Plays a Part
    • 3.5.1. Hospital Testing Share
    • 3.5.2. Economies of Scale
  • 3.5.2.1. Hospital vs. Central Lab
    • 3.5.3. Physician Office Lab's
    • 3.5.4. Physician's and POCT
  • 3.6. Currently Available Large Comprehensive Assays
  • 3.7. Pricing Profiling vs. Whole Exome (or Genome) Sequencing
    • 3.7.1. Medicare Profile Pricing
    • 3.7.2. Whole Exome Sequencing

4. Market Trends

  • 4.1. Factors Driving Growth
    • 4.1.1. Level of Care
    • 4.1.2. Companion Dx
    • 4.1.3. Immuno-oncology
    • 4.1.4. Liability
    • 4.1.5. Aging Population
  • 4.2. Factors Limiting Growth
    • 4.2.1. State of knowledge
    • 4.2.2. Genetic Blizzard
    • 4.2.3. Protocol Resistance
    • 4.2.4. Regulation and coverage
  • 4.3. Instrumentation and Automation
    • 4.3.1. Instruments Key to Market Share
    • 4.3.2. Bioinformatics Plays a Role
  • 4.4. Diagnostic Technology Development
    • 4.4.1. Next Generation Sequencing Fuels a Revolution
    • 4.4.2. Single Cell Genomics Changes the Picture
    • 4.4.3. Pharmacogenomics Blurs Diagnosis and Treatment
    • 4.4.4. CGES Testing, A Brave New World
    • 4.4.5. Biochips/Giant magneto resistance based assay

5. Cancer Panels & Profiles Recent Developments

  • 5.1. Recent Developments-Importance and How to Use This Section
    • 5.1.1. Importance of These Developments
    • 5.1.2. How to Use This Section
  • 5.2. Dante Labs Acquires Cambridge Cancer Genomics
  • 5.3. Celemics, Strand Partner on Integrated Platform for NGS Analysis
  • 5.4. Myriad Genetics Recalibrates Breast Cancer Panel for All Ancestries
  • 5.5. Burning Rock Revenues Rise
  • 5.6. Caris Life Sciences to Expand Liquid Biopsy Testing
  • 5.7. OncoDiag Announces Multiplex Test for Bladder Cancer Recurrence
  • 5.8. Intermountain and Myriad Combine Test Offering
  • 5.9. Illumina, Geneseeq to Offer Cancer Testing Kits in China
  • 5.10. Exact Sciences to Offer End-to-End Cancer Testing
  • 5.11. Guardant Health Turns to Tumor Tissue Sequencing
  • 5.12. Tempus Inks Oncology Testing Collaboration With Bayer
  • 5.13. Biocartis Collaborating With GeneproDx, Endpoint Health on Tests for Idylla Platform
  • 5.14. Wales to Routinely Screen Cancer Patients With Yourgene Elucigene Test
  • 5.15. Metastatic Cancer Markers Identified in Clinical WGS Study
  • 5.16. Stitch Bio Bets on CRISPR Tech
  • 5.17. Bayer, LifeLabs Launch Free NTRK Genetic Testing Program
  • 5.18. Foundation Medicine Liquid Biopsy Gets FDA Approval for Multiple Companion
  • 5.19. Progress, Challenges in Liquid Biopsy Reimbursement
  • 5.20. Israeli Startup Curesponse Raises $6M
  • 5.21. Invitae, ArcherDX Merge to Advance Precision Oncology Offerings
  • 5.22. MD Anderson Precision Oncology Decision Support to Use Philips' Informatics Solution
  • 5.23. NeoGenomics, Lilly Oncology Partner for Thyroid Cancer Testing Program
  • 5.24. Germline Results Guides Precision Therapy in Advanced Cancer
  • 5.25. FDA Clears Cancer Genomic Profiling Kit From Personal Genome Diagnostics
  • 5.26. ArcherDX, Premier Collaborate to Evaluate Genomic Sequencing Assay for Cancers
  • 5.27. Labs Reporting Cancer Risk Mutations from Tumor Testing
  • 5.28. Users Begin Integrating Genomics Data for Clinical Decision Support
  • 5.29. Fujitsu Improves Efficiency in Cancer Genomic Medicine
  • 5.30. Thermo Fisher's automated sequencer to offer same-day, pan-cancer test results
  • 5.31. Universal Genetic Testing for All Breast Cancer Patients
  • 5.32. Exact Sciences buys Genomic Health
  • 5.33. Multi-Gene Liquid Biopsy Breast Cancer Panel
  • 5.34. Thrive to Develop Earlier Detection of Multiple Cancer Types
  • 5.35. New Gene Panel Identifies High Risk Prostate Cancer
  • 5.36. Guardant Health Liquid Biopsy Test to be Covered by EviCore
  • 5.37. Biocept Partnership Offering for Liquid Biopsy Adds Several Key Services
  • 5.38. Natera Commercializes Tumor Whole Exome Sequencing from Plasma
  • 5.39. Inivata Completes £39.8M Series B Funding Round
  • 5.40. Bio-Rad Clinical ddPCR Test, Diagnostic System Get FDA Clearance
  • 5.41. CellMax, Medigen Biotech Partner in Colorectal Cancer Clinical Trials
  • 5.42. Biodesix Acquires Integrated Diagnostics
  • 5.43. Predicine, Kintor Pharmaceuticals Partner on Clinical Trials, CDx

6. Profiles of Key Players

  • 6.1. 10x Genomics, Inc
  • 6.2. Abbott Diagnostics
  • 6.3. AccuraGen Inc.
  • 6.4. Adaptive Biotechnologies
  • 6.5. Aethlon Medical
  • 6.6. Agena Bioscience, Inc.
  • 6.7. Agilent/Dako
  • 6.8. Anchor Dx
  • 6.9. ANGLE plc
  • 6.10. ApoCell, Inc.
  • 6.11. ArcherDx, Inc.
  • 6.12. ARUP Laboratories
  • 6.13. Asuragen
  • 6.14. AVIVA Biosciences
  • 6.15. Baylor Miraca Genetics Laboratories
  • 6.16. Beckman Coulter Diagnostics
  • 6.17. Becton, Dickinson and Company
  • 6.18. BGI Genomics Co. Ltd
  • 6.19. Bioarray Genetics
  • 6.20. Biocartis
  • 6.21. Biocept, Inc
  • 6.22. Biodesix Inc.
  • 6.23. BioFluidica
  • 6.24. BioGenex
  • 6.25. BioIVT
  • 6.26. Biolidics Ltd
  • 6.27. bioMérieux Diagnostics
  • 6.28. Bioneer Corporation
  • 6.29. Bio-Rad Laboratories, Inc
  • 6.30. Bio-Reference Laboratories
  • 6.31. Bio-Techne
  • 6.32. Bioview
  • 6.33. Bolidics
  • 6.34. Boreal Genomics
  • 6.35. Bristol-Myers Squibb
  • 6.36. Burning Rock
  • 6.37. Cancer Genetics
  • 6.38. Caris Molecular Diagnostics
  • 6.39. Castle Biosciences, Inc.
  • 6.40. Celemics
  • 6.41. CellMax Life
  • 6.42. Cepheid (Danaher)
  • 6.43. Charles River Laboratories
  • 6.44. Chronix Biomedical
  • 6.45. Circulogene
  • 6.46. Clinical Genomics
  • 6.47. Cynvenio
  • 6.48. Cytolumina Technologies Corp.
  • 6.49. CytoTrack
  • 6.50. Datar Cancer Genetics Limited
  • 6.51. Diagnologix LLC
  • 6.52. Diasorin S.p.A.
  • 6.53. Enzo Life Sciences, Inc.
  • 6.54. Epic Sciences
  • 6.55. Epigenomics AG
  • 6.56. Eurofins Scientific
  • 6.57. Exact Sciences
  • 6.58. Exosome Diagnostics
  • 6.59. Exosome Sciences
  • 6.60. Fabric Genomics
  • 6.61. Fluidigm Corp
  • 6.62. Fluxion Biosciences
  • 6.63. Foundation Medicine
  • 6.64. Freenome
  • 6.65. FUJIFILM Wako Diagnostics
  • 6.66. GeneFirst Ltd.
  • 6.67. Genetron Holdings
  • 6.68. GenomOncology
  • 6.69. GILUPI Nanomedizin
  • 6.70. Grail, Inc
  • 6.71. Guardant Health
  • 6.72. HalioDx
  • 6.73. HansaBiomed
  • 6.74. HeiScreen
  • 6.75. Helomics
  • 6.76. Horizon Discovery
  • 6.77. HTG Molecular Diagnostics
  • 6.78. iCellate
  • 6.79. Illumina
  • 6.80. Incell Dx
  • 6.81. Inivata
  • 6.82. Integrated Diagnostics
  • 6.83. Invitae Corporation
  • 6.84. Invivogen
  • 6.85. Invivoscribe
  • 6.86. Janssen Diagnostics
  • 6.87. MDNA Life SCIENCES, Inc
  • 6.88. MDx Health
  • 6.89. Menarini Silicon Biosystems
  • 6.90. Millipore Sigma
  • 6.91. Miltenyi Biotec
  • 6.92. MIODx
  • 6.93. miR Scientific
  • 6.94. Molecular MD
  • 6.95. MyCartis
  • 6.96. Myriad Genetics/Myriad RBM
  • 6.97. NantHealth, Inc.
  • 6.98. Natera
  • 6.99. NeoGenomics
  • 6.100. New Oncology
  • 6.101. NGeneBio
  • 6.102. Novogene Bioinformatics Technology Co., Ltd.
  • 6.103. Oncocyte
  • 6.104. OncoDNA
  • 6.105. Ortho Clinical Diagnostics
  • 6.106. Oxford Nanopore Technologies
  • 6.107. Panagene
  • 6.108. Perkin Elmer
  • 6.109. Personal Genome Diagnostics
  • 6.110. Personalis
  • 6.111. Precipio
  • 6.112. PrecisionMed
  • 6.113. Promega
  • 6.114. Qiagen Gmbh
  • 6.115. Rarecells SAS
  • 6.116. RareCyte
  • 6.117. Roche Molecular Diagnostics
  • 6.118. Screencell
  • 6.119. Sense Biodetection
  • 6.120. Serametrix
  • 6.121. Siemens Healthineers
  • 6.122. Silicon Biosystems
  • 6.123. simfo GmbH
  • 6.124. Singlera Genomics Inc
  • 6.125. Singulomics
  • 6.126. SkylineDx
  • 6.127. Stratos Genomics
  • 6.128. Sysmex Inostics
  • 6.129. Tempus Labs, Inc.
  • 6.130. Thermo Fisher Scientific Inc
  • 6.131. Thrive Earlier Detection
  • 6.132. Todos Medical
  • 6.133. Trovagene
  • 6.134. Variantyx
  • 6.135. Volition
  • 6.136. Vortex Biosciences

7. The Global Market for Cancer Gene Panels and Profiles

  • 7.1. Global Market Overview by Country
    • 7.1.1. Table-Global Market by Country
    • 7.1.2. Chart-Global Market by Country
  • 7.2. Global Market by Cancer Type-Overview
    • 7.2.1. Table-Global Market by Cancer Type
    • 7.2.2. Chart-Global Market by Cancer Type-Base/Final Year Comparison
    • 7.2.3. Chart-Global Market by Cancer Type-Base Year
    • 7.2.4. Chart-Global Market by Cancer Type-Final Year
    • 7.2.5. Chart-Global Market by Cancer Type-Share by Year
    • 7.2.6. Chart-Global Market by Cancer Type-Segment Growth
  • 7.3. Global Market by Application-Overview
    • 7.3.1. Table-Global Market by Application
    • 7.3.2. Chart-Global Market by Application-Base/Final Year Comparison
    • 7.3.3. Chart-Global Market by Application-Base Year
    • 7.3.4. Chart-Global Market by Application-Final Year
    • 7.3.5. Chart-Global Market by Application-Share by Year
    • 7.3.6. Chart-Global Market by Application-Segment Growth
  • 7.4. Global Market by Tissue-Overview
    • 7.4.1. Table-Global Market by Tissue
    • 7.4.2. Chart-Global Market by Tissue-Base/Final Year Comparison
    • 7.4.3. Chart-Global Market by Tissue-Base Year
    • 7.4.4. Chart-Global Market by Tissue-Final Year
    • 7.4.5. Chart-Global Market by Tissue-Share by Year
    • 7.4.6. Chart-Global Market by Tissue-Segment Growth
  • 7.5. Global Market Germline & Somatic-Overview
    • 7.5.1. Table-Global Market Germline & Somatic
    • 7.5.2. Chart-Global Market Germline & Somatic-Base/Final Year Comparison
    • 7.5.3. Chart-Global Market Germline & Somatic-Base Year
    • 7.5.4. Chart-Global Market Germline & Somatic-Final Year
    • 7.5.5. Chart-Global Market Germline & Somatic-Share by Year
    • 7.5.6. Chart-Global Market Germline & Somatic-Segment Growth

8. Global Cancer Gene Panels & Profiles Markets-By Type of Cancer

  • 8.1. Comprehensive Panels & Profiles
    • 8.1.1. Table Comprehensive Testing-by Country
    • 8.1.2. Chart-Comprehensive Testing Growth
  • 8.2. Breast Cancer Gene Testing
    • 8.2.1. Table Breast Cancer Gene Testing-by Country
    • 8.2.2. Chart-Breast Cancer Testing Growth
  • 8.3. Colorectal Cancer Gene Testing
    • 8.3.1. Table Colorectal Cancer Gene Testing-by Country
    • 8.3.2. Chart-Colorectal Cancer Gene Testing Growth
  • 8.4. Gynecological Cancer Gene Testing
    • 8.4.1. Table Gynecological Cancer Gene Testing-by Country
    • 8.4.2. Chart-Gynecological Cancer Gene Testing Growth
  • 8.5. Blood Cancer Gene Testing
    • 8.5.1. Table Blood Cancer Gene Testing-by Country
    • 8.5.2. Chart-Blood Cancer Gene Testing Growth
  • 8.6. Prostate Cancer Gene Testing
    • 8.6.1. Table Prostate Cancer Gene Testing-by Country
    • 8.6.2. Chart-Prostate Cancer Testing Growth
  • 8.7. Lung Cancer Gene Testing
    • 8.7.1. Table Lung Cancer Gene Testing-by Country
    • 8.7.2. Chart-Lung Cancer Gene Testing Growth
  • 8.8. Other Cancer Gene Testing
    • 8.8.1. Table Other Cancer Gene Testing-by Country
    • 8.8.2. Chart-Other Cancer Gene Testing Growth

9. Global Cancer Gene Panels & Profiles Markets-By Type of Application

  • 9.1. Clinical Testing
    • 9.1.1. Table Clinical Testing-by Country
    • 9.1.2. Chart-Clinical Testing Growth
  • 9.2. Pharmaceutical Testing
    • 9.2.1. Table Pharmaceutical Testing-by Country
    • 9.2.2. Chart-Pharmaceutical Testing Growth
  • 9.3. Research Testing
    • 9.3.1. Table Research Testing-by Country
    • 9.3.2. Chart-Research Testing Growth

10. Global Cancer Gene Panels & Profiles Markets-By Tissue Type

  • 10.1. Solid Tissue
    • 10.1.1. Table Solid Tissue Testing-by Country
    • 10.1.2. Chart-Solid Tissue Testing Growth
  • 10.2. Liquid Tissue Testing
    • 10.2.1. Table Liquid Tissue Testing-by Country
    • 10.2.2. Chart-Liquid Tissue Testing Growth

11. Global Cancer Gene Testing Markets-Germline and Somatic

  • 11.1. Global Market Somatic
    • 11.1.1. Table Somatic-by Country
    • 11.1.2. Chart-Somatic Testing Growth
  • 11.2. Global Market Germline
    • 11.2.1. Table Germline-by Country
    • 11.2.2. Chart-Germline Testing Growth

12. Potential Market Opportunity Sizes

  • 12.1. Potential Cancer Screening by Country: Lung, Breast & Colorectal
  • 12.2. Potential Cancer Screening by Country: Prostate, Other Cancer & All Cancer
  • 12.3. Potential Market Size-Cancer Diagnosis
  • 12.4. Potential Market Size-Therapy Selection

13. Appendices

  • 13.1. Quarterly Actuals and Forecast Volumes and Revenues for Foundation Medicine and Guardant Health
  • 13.2. United States Medicare System: January 2021 Clinical Laboratory Fees Schedule
  • 13.3. FDA Approved Human Genetic Tests
  • 13.4. Pharmacogenomic Biomarkers in Drug Labeling
  • 13.5. FDA Approved Pharmacogenomics Tests